Document Detail


Familial aggregation of bothersome benign prostatic hyperplasia symptoms.
MedLine Citation:
PMID:  12670565     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate familial aggregation and the mode of inheritance of bothersome benign prostatic hyperplasia (BPH). METHODS: During an extension of the North American Finasteride Trial, 301 of 895 patients and 158 spousal controls completed a family history questionnaire. Segregation analysis was performed to examine the mode of inheritance in first-degree relatives of the 301 probands. RESULTS: The lifetime cumulative probability of bothersome BPH was similar in relatives of those with BPH (0.35; 95% confidence interval [CI] 0.28 to 0.44) and spousal controls (0.36; 95% CI 0.22 to 0.56), but the age of onset was significantly earlier in relatives of cases than controls (P = 0.001). Fathers of those with BPH had a significantly elevated risk of bothersome BPH (unadjusted odds ratio [OR] 2.1; 95% CI 1.2 to 3.8) and brothers had a significantly elevated risk of both bothersome BPH (OR 3.5; 95% CI 1.7 to 7.3) and transurethral resection of the prostate (OR 3.6; 95% CI 1.4 to 8.8). After adjusting for family size, the risk of bothersome BPH increased approximately twofold with each additional affected first-degree relative (0 relatives, OR 1.0; 1 relative, OR 1.7; 2 relatives, OR 4.7). Segregation analysis suggested a rare autosomal codominant allele (frequency 0.0004). CONCLUSIONS: These findings confirm previous findings that family history and early age of onset are associated with an increased risk of BPH and that the most likely mode of inheritance is autosomal dominant or codominant. Bothersome BPH appears to have a weaker genetic component than more restrictive definitions of hereditary BPH. Thus, linkage studies are more likely to be successful if they focus on stricter definitions of hereditary BPH (eg, early onset, large volume, strong family history) rather than symptomatic or clinical BPH.
Authors:
Jay D Pearson; Hsien-Hsien Lei; Terri H Beaty; Kathleen E Wiley; Sarah D Isaacs; William B Isaacs; Elizabeth Stoner; Patrick C Walsh
Related Documents :
24198885 - Utilization of malaria prevention methods by pregnant women in yaounde.
23597395 - Prevalence of waterpipe tobacco smoking among population aged 15 years or older, vietna...
23131465 - The risk of small ruminant lentivirus (srlv) transmission with reproductive biotechnolo...
23719715 - Men who purchase sex, who are they? an interurban comparison.
15824335 - Risk of stevens-johnson syndrome and toxic epidermal necrolysis in new users of antiepi...
25088805 - Parental occupational paint exposure and risk of childhood leukemia in the offspring: f...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Urology     Volume:  61     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-04-02     Completed Date:  2003-08-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  781-5     Citation Subset:  IM    
Affiliation:
Department of Epidemiology, Merck Research Laboratories, Merck and Co., Inc., West Point, Pennsylvania 19486-0004, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age of Onset
Aged
Case-Control Studies
Family Health*
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Models, Genetic
Prostatic Hyperplasia / diagnosis*,  epidemiology,  genetics*
Prostatic Neoplasms / epidemiology,  genetics,  surgery
Regression Analysis
Survival Analysis
Transurethral Resection of Prostate / statistics & numerical data
Grant Support
ID/Acronym/Agency:
1 P41 RR03655/RR/NCRR NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Next Document:  Nocturia and benign prostatic hyperplasia.